FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office			ATTY. DOCKET: 2003080-0143	1	TION NO.:
		196	(SK-744-CON9) 10/726,386		6
(Use several sheets if necessary) MAR 2 6 2024		APPLICANT: Danishefsky et al			
		FILING DATE:	GROUP:		
		\z <u>\\</u>	December 2, 2003	<u></u>	
	T DOCUMENTS	Applicant	T	T	T
Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Initials	*(000 (01	Custofoon	July 19, 2000	435.	183
40	*6,090,601	Gustafsson	July 18, 2000		
	*6,096,757	Bishop	August 1, 2000	514	290
	*6,117,659	Ashley	September 12, 2000	435	155
	*6,121,029	Schupp	September 19, 2000	435	183
	*6,211,412	Georg	April 3, 2001	568	309
	*6,221,641	Khosla	April 24, 2001	435	193
	*6,251,636	Betlach	June 26, 2001	435	76
	*6,262,107	Li	July 17, 2001	. 514	449
	*6,280,999	Gustafsson	August 28, 2001	.435	252.3
	*6,407,103	Nugiel et al.	June 18, 2002 ·	514	232.8
	*6,489,314	Ashley et al.	December 3, 2002	514	183
	*6,498,257	Vite et al.	December 24, 2002	548	205
	*6,515,017	Li et al.	February 4, 2003	514	449
	*6,518,421	Li et al.	February 11, 2003	540	462
	*6,525,197	Furstner et al.	February 25, 2003	544	310
	*6,531,497	Nicolaou et al.	March 11, 2003	514	370
	*6,537,988	Lee	March 25, 2003	514	221
	*6,538,038	Pero et al.	March 25, 2003	514	731
	*6,544,544	Hunter et al.	April 8, 2003	424	424
	*6,576,651	Bandyopadhyay et al.	June 10, 2003	514	365
	*6,593,115	Vite et al.	July 15, 2003	435	134
	*6,596,875	White et al.	July 22, 2003	548	204
	*6,603,015	Georg et al.	August 5, 2003	548	203
	*6,603,023	Danishefsky et al.	August 5, 2003	549	346
	*6,605,599	Vite et al.	August 12, 2003	514	63
	*6,605,726	Mulzer et al.	August 12, 2003	548	202
	*6,610,736	Klar et al.	August 26, 2003	514	450
	*6,613,912	Hoefle et al.	September 2, 2003	548	204

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.: 10/726,386		
	TION DISCLOSURE		APPLICANT: Danishefsky et al		
(Use several sheets if necessary)		FILING DATE: December 2, 2003	GROUP:		
40.	*6,624,310	Hoefle et al.	September 23, 2003	548	204
	*6,664,288	Pardee et al.	December 16, 2003	514	449
	*6,670,384	Bandyopadhyay et al.	December 30, 2003	514	365
V	*6,683,100	Van Hoogevest	January 27, 2004	514	365
U.S. PATEN	NT APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
70	*2002/0086812	Schweinfest et al.	July 4, 2002		
1	*2002/0091269	Avery	July 11, 2002		
	*2002/0094991	Gallaher	July 18, 2002		
	*2002/0115686	Hoogevest	August 22, 2002		
	*2002/0119202	Hunter et al.	August 29, 2002		
	*2002/0137152	Santi et al.	September 26, 2002		
	*2002/0147197	Newman et al.	October 10, 2002		
	*2002/0156110	Arslanian et al.	October 24, 2002		
	*2002/0156289	Georg et al.	October 24, 2002		
	*2002/0164377	Hunter et al.	November 7, 2002		
	*2002/0165258	Lee	November 7, 2002		
	*2002/0165256	Hofmann et al.	November 7, 2002		
	*2002/0165257	Lee	November 7, 2002		
	*2002/0165265	Hunter et al.	November 7, 2002		
	*2002/0165415	Georg et al.	November 7, 2002		
	*2002/0169125	Leung et al.	November 14, 2002		
	*2002/0169135	Pardee et al.	November 14, 2002		
	*2002/0169190	Bandyopadhyay et al.	November 14, 2002		
	*2002/0177615	Bandyopadhyay et al.	November 28. 2002		
	*2002/0192778	Schupp et al.	December 19, 2002		
	*2002/0193361	Ashley et al.	December 19, 2002		
	*2002/0197261	Li et al.	December 26, 2002		
V	*2002/0198141	McChesney et al.	December 26, 2002		

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION NO.:	
			(SK-744-CON9)	10/726,386
	ATION DISCLOSURE		APPLICANT: Danishefsky et al	
(Us	(Use several sheets if necessary)		FILING DATE:	GROUP:
			December 2, 2003	
Yo	*2003/0232968	Li et al.	December 18, 2003	·
<u>'\</u>	*2003/0232837	Guzi et al.	December 18, 2003	
	*2003/0232416	Wong et al.	December 18, 2003	
	*2003/0235855	Cabral	December 25, 2003	
	*2003/0166507	Li et al.	September 4, 2003	
	*2003/0158412	Westermann et al.	August 21, 2003	
	*2003/0149281	Westermann et al.	August 7, 2003	·
	*2003/0147807	Li et al.	August 7, 2003	
	*2003/0144533	Iwasaki et al.	July 31, 2003	
	*2003/0144523	Klar et al.	July 31, 2003	
	*2003/0139460	Schwede et al.	July 24, 2003	
	*2003/0134883	Myles et al.	July 17, 2003	
	*2003/0130178	Li et al.	July 10, 2003	·
	*2003/0130170	Li et al.	July 10, 2003	
	*2003/0124055	Li et al.	July 3, 2003	
	*2003/0125362	Danishefsky	July 3, 2003	
	*2003/0113335	Li et al.	June 19, 2003	
	*2003/0114363	Li et al.	July 3, 2003	
	*2003/0114450	Santi et al.	June 19, 2003	
	*2003/0114504	Webster et al.	June 19, 2003	
	*2003/0114518	Li et al.	June 19, 2003	
	*2003/0105330	Danishefsky et al.	June 5, 2003	
1	*2003/0109500	Pero et al.	June 12, 2003	
	*2003/0096381	Julien et al.	May 22, 2003	
	*2003/0087888	Regueiro-Ren et al.	May 8, 2003	
	*2003/0073677	Lee	April 17, 2003	
	*2003/0073617	Li et al.	April 17, 2003	
	*2003/0073615	Li et al.	April 17,. 2003	
	*2003/0073205	Arslanian et al.	April 17, 2003	
	*2003/0069277	Danishefsky et al.	April 10, 2003	
	*2003/0060623	Vite et al.	March 27, 2003	·
-V	*2003/0054977	Kumar et al.	March 20, 2003	

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET: 2003080-0143	IN RE APPLICA 10/726,386	ΓΙΟΝ NO.:
			(522.1.1.00.1.5))
	several sheets if necessor		APPLICANT: Danishefsky et al		
(Use several sneets if necessary)			FILING DATE:	GROUP:	
		December 2, 2003		1	
70	*2003/0049841	Short et al.	March 13, 2003	-	
	*2003/0045711	Ashley et al.	March 6, 2003		1
	*2003/0036515	Pardee et al.	February 20, 2003	-	
	*2003/0036177	Strohhacker	February 20, 2003	<u> </u>	
	*2003/0023082	Ashley et al.	January 30, 2003		
	*2003/0004338	Li et al.	January 2, 2003		ļ
	*2003/0004209	Hunter et al.	January 2, 2003		
	*2003/0003094	Hunter et al.	January 2, 2003		ļ
	*2003/0191089	Regueiro-Ren et al.	October 9, 2003		
	*2003/0187273	White et al.	October 2, 2003		
	*2003/0187039	Favreau et al.	October 2, 2003		
	*2003/0186983	Mastalerz et al.	October 2, 2003		
	*2003/0186965	Vite et al.	October 2, 2003		
	*2003/0185831	Cutler et al.	October 2, 2003		
	*2003/0180760	Basch et al.	September 25, 2003		
	*2003/0176710	Klar et al.	September 18, 2003		
	*2003/0176473	Taylor et al.	September 18, 2003		
	*2003/0176368	Danishefsky	September 18, 2003		
	*2003/0176320	Li et al.	September 18, 2003		
	*2003/0166507	Li et al.	September 4, 2003		
	*2004/0014982	Hoefle et al.	January 22, 2004		
	*2004/0014978	Klar et al.	January 22, 2004	·	
	*2004/0006087	Cutler et al.	January 8, 2004		
	*2003/0166507	Li et al.	September 4, 2003		
	*2004/0019088	Lichtner et al	January 29, 2004		
	*2004/0018598	Santi et al.	January 29, 2004		
	*2004/0014982	Hoefle et al.	January 22, 2004		
	*2004/0014978	Klar et al.	January 22, 2004		
V	*2004/0006087	Cutler et al.	January 8, 2004		
FOREIGN	PATENT DOCUMEN	rs	<u>. </u>		
Examiner's	Document No.	Country	Date	Translation	1
Initials		1		Yes	No

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.: 10/726,386	
INFORMA	ATION DISCLOSURE	STATEMENT	APPLICANT: Danishefsky et al	
(Use several sheets if necessary)		FILING DATE:	GROUP:	
			December 2, 2003	GROOT.
Yo	*DE 41 38 042	Germany	19 November 1991	·
10	*DE 41 38 042	Germary	19 November 1991	<u> </u>
	*DE 196 07 702	Germany	29 February 1996	-
	*DE 196 36 343	Germany	30 August 1996	
	*DE 196 38 870	Germany	23 September 1996	1-
	*DE 196 47 580.5		18 November 1996	
		Germany		
	*DE 197 01 758	Germany	20 January 1997	
	*DE 197 07 506.1	Germany	25 February 1997	
	*DE 197 13 970	Germany	04 April 1997	
	*DE 197 20 312	Germany	15 May 1997	
	*DE 197 26 627	Germany	17 June 1997	
	*DE 197 35 574	Germany	09 August 1997	
	*DE 197 35 575	Germany	09 August 1997	
	*DE 197 35 578	Germany	09 August 1997	
	*DE 197 44 135	Germany	29 September 1997	
	*DE 197 49 717	Germany	31 October 1997	
	*DE 197 51 200	Germany	13 November 1997	
	*DE 198 13 821	Germany	20 March 1998	
	*DE 198 21 954	Germany	15 May 1998	
	*DE 198 33 750	Germany	16 July 1998	
	*DE 198 46 493	Germany	09 October 1998	
	*DE 198 30 060	Germany	30 June 1998	
	*DE 198 49 464	Germany	21 October 1998	
	*DE 199 07 588	Germany	22 February 22, 1999	
	*DE 199 08 763	Germany	18 February 1999	
	*DE 199 08 765	Germany	18 February 1999	
	*DE 199 21 086	Germany	30 April 1999	
	*DE 199 23 001	Germany	13 May 1999	
	*DE 199 30 111	Germany	01 July 1999	
	*DE 199 54 228	Germany	04 November 1999	
	*DE 199 54 230	Germany	04 November 1999	
	*DE 100 51 136	Germany	16 October 2000	

FORM PTO-1449 U.S. Department of Commerce		ATTY. DOCKET:	IN RE	
(REV. 8-83) Patent and Trademark Office		2003080-0143	APPLICATION NO.:	
		(SK-744-CON9) 10/726,386		
	INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefsky et al	
(Use	several sheets if necessar	אי	FILING DATE:	GROUP:
			December 2, 2003	
70	*DE 100 15 836	Germany	27 March 2000	
	*DE 100 20 517	Germany	19 April 2000	
	*DE 100 20 899	Germany	20 April 2000	
	*EP 1 275 648	Europe	15 January 2003	
	*EP 1 201 666	Europe	02 May 2002	
	*EP 1 201 666	Europe	05 February 2002	
	*EP 1 186 606	Europe	13 March 2002	
	*EP 1 121 364	Europe	13 March 2002	
	*EP 1 087 975	Europe	27 August 2003	
	*EP 1 077 980	Europe	19 March 2003	
	*EP 1 042 327	Europe	17 September 2003	
	*EP 1 140 944	Europe	27 August 2003	
	*EP 1 340 498	Europe	03 September 2003	
	*EP 1 001 951	Europe	25 September 2002	
, ,	*EP 0 975 638	Europe	07 August 2002	
V	*EP 0 975 622	Europe	09 October 2002	
	*EP 0 903-348	Europe	No Publication	date
40	*EP 0 873 341	Europe	10 September 2003	
	*199 08 760	DE	24 August 2000	
	*199 08 767	DE	19 October 2000	
	*WO 2004/007476	PCT	22 January 2004	
	*WO 03/105828	PCT	24 December 2003	
	*WO 03/103712	PCT	18 December 2003	
	*WO 03/084536	PCT	16 October 2003	
	*WO 03/078411	PCT	25 September 2003	
	*WO 03/077903	PCT	25 September 2003	
	*WO 03/076445	PCT	. 18 September 2003	
	*WO 03/075899	PCT	18 September 2003	
	*WO 03/074521	PCT	12 September 2003	
	*WO 03/074053	PCT	12 September 2003	
	*WO 03/070170	PCT	13 February 2002	
\/	*WO 03/057830	PCT	17 December 2002	

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office			ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.: 10/726,386
INFORMA	TION DISCLOSURE S	TATEMENT	APPLICANT: Danishefsky et al	
	(Use several sheets if necessary)		FILING DATE:	GROUP:
		December 2, 2003	GROOF.	
V0	*WO 03/057217	PCT	13 January 2003	
7,	*WO 03/053949	PCT	23 December 2002	
	*WO 03/049734	PCT	19 June 2003	
	*WO 03/045324	PCT	05 June 2003	
	*WO 03/042217	PCT	22 May 2003	
	*WO 03/029260	PCT	10 April 2003	· · · · · ·
	*WO 03/029195	PCT	10 April 2003	
	*WO 03/026744	PCT	03 April 2003	
	*WO 03/018002	PCT	06 March 2003	
	*WO 03/014068	PCT	20 February 2003	
	*WO 03/014063	PCT	20 February 2003	
	*WO 03/007924	PCT	30 January 2003	
	*WO 02/46196	PCT	13 June 2002	
	*WO 02/42432	PCT	30 May 2002	
	*WO 02/32844	PCT .	16 October 2001	
	*WO 02/30356	PCT	15 October 2001	
	*WO 02/098868	PCT	14 May 2002	
	*WO 02/080846	PCT	17 October 2002	
	*WO 02/074042	PCT	26 September 2002	
	*WO 02/072858	PCT	27 February 2002	
	*WO 02/072085	PCT	19 September 2002	
	*WO 02/067941	PCT	06 September 2002	
	*WO 02/066038	PCT	06 February 2002	
	*WO 02/066033	PCT	29 August 2002	
	*WO 02/062338	PCT	15 August 2002	
	*WO 02/060904	PCT	08 August 2002	
	*WO 02/058701	PCT	01 August 2002	
	*WO 02/058700	PCT	01 August 2002	
	*WO 02/058699	PCT	01 August 2002	
	*WO 01/81342	PCT	19 April 2001	
	*WO 01/81341	PCT	19 April 2001	
V	*WO 01/73103	PCT	23 March 2001	

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION NO.:	
TAUTO DAY	TION DIOCE COLIDS		(SK-744-CON9)	10/726,386
	ATION DISCLOSURE : e several sheets if necesse		APPLICANT: Danishefsky et al	
(03	e several sheets if hecessi	uy)	FILING DATE:	GROUP:
	T	T	December 2, 2003	
70	*WO 01/70716	PCT	12 March 2001	
	*WO 01/66154	PCT	09 March 2001	
	*WO 01/64650	PCT	01 March 2001	
	*WO 01/27308	PCT	06 October 2000	
	*WO 01/10412	PCT	02 August 2000	
	*WO 01/92255	PCT	06 December 2001	
	*WO 01/83800	PCT	08 November 2001	
	*WO 01/07439	PCT	24 July 2000	
	*WO 00/71521	PCT	15 May 2000	
	*WO 00/66589	PCT	01 May 2000	
	*WO 00/58254	PCT	23 March 2000	
	*WO 00/57874	PCT	20 March 2000	
	*WO 00/50423	PCT	17 February 2000	
	*WO 00/49021	PCT	18 February 2000	
	*WO 00/49020	PCT	18 February 2000	
	*WO 00/49019	PCT	18 February 2000	
	*WO 00/047584	PCT	11 February 2000	
	*WO 00/39276	PCT	21 December 1999	
	*WO 00/37473	PCT	20 December 1999	
	*WO 00/31247	PCT	19 November 1999	
	*WO 00/00485	PCT	30 June 1999	
	*WO 99/67253	PCT	21 June 1999	
	*WO 99/67252	PCT	21 June 1999	
	*WO 99/66028	PCT	16 June 1999	
- -	*WO 99/65913	PCT	18 June 1999	
	*WO 99/59985	PCT	14 May 1999	
	*WO 99/58534	PCT	07 May 1999	
	*WO 99/54330	PCT	14 April 1999	
	*WO 99/54319	PCT	05 April 1999	
	*WO 99/54318	PCT	05 April 1999	
	*WO 99/43653	PCT	24 February 1999	
- \ /	*WO 99/43320	PCT	23 February 1999	

FORM PTO-1449 U.S. Department of Commerc			ATTY. DOCKET:	IN RE	
(REV. 8-83)	(REV. 8-83) Patent and Trademark Office		2003080-0143 (SK-744-CON9)	APPLICATION NO.: 10/726,386	
INFORMA	TION DISCLOSURE ST	TATEMENT	APPLICANT: Danisher	skv et al	
(Use	(Use several sheets if necessary)		FILING DATE: December 2, 2003	GROUP:	
70	*WO 99/42602	PCT	17 February 1999		
	*WO 99/39694	PCT	03 February 1999		
	*WO 98/54966	PCT	04 June 1998		
1	*WO 98/25929	PCT	18 June 1998		
OTHER DO	CUMENTS				
Examiner's Initials		hor, Title, Date, Pertinen			
10			ale Stabilizing Antitumor rpless' Asymmedtric Epo		
			ures - a new class of micr		
			mica et Biophysica Acta, s-Potential New Weapon		
	Cancer", Chimia, 54: 61		s-rotential New Weapon	s in the right Against	
	*Altmann, et al., "Synthesis and Biological Evaluation of Highly Potent Analogues of Epothilones B and D. <i>Bioorg. Med. Chem. Lett.</i> , 10(24): 2765-2768, 2000.				
			etures-A New Class of Mi		
			phys. Acta., 1470(3): M7 Analogs of Epothilones: (
	Activity"	·			
	1999.		San Francisco, CA, Marc		
		_	uation of Aza-Epothilone	s" ChemBioChem	
		Engl.), 1(1)/39(3): 67-70	ts: A Growing Class of I	mportant Anticancer	
	Drugs" Curr. Opin. Che	em. Biol., 5(4): 424-431,	2001.		
	11(9): 678-696, 1998.		es: Highlights from a Yea		
		•	from Modified Polyketic		
			hus" J. Nat. Prod., 65: 10 on Tumor Cells", Cancer		
	, ,		cular-Targeted Therapies		
1	Metastatic Breast Cance	er Review, 4-15, 2002.			
	· · · · · · · · · · · · · · · · · · ·	•	d Aldol and Michael Cyc	ioreductions,	
	J.Am. Chem. Soc., 123: 5112-5113, 2001. *Balog, et al., "A Novel Aldol Condensation with 2-Methyl-4-Pentenal and Its Application to an Improved Total Synthesis of Epothilone B", Angew. Chem. Int. Ed. 37(19): 2675-2678, 1998.				
			', Angew Chem. Int. Ed. 6		
\bigvee	*Bellemin-Laponnaz, et al., "The Kinetic Resolution of Allylic Alchols by a Non-Enzymatic Acylation Catalyst: Application to Natural Product Synthesis" Chem. Commun., 12: 1009-1010,				

FORM PT	O-1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83	3)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:	
	•		(SK-744-CON9)	10/726,386	
INFORMA	ATION DISC	LOSURE STATEMENT	APPLICANT: Danishefsky et al		
(Us	e several shee	ts if necessary)	FILING DATE:	GROUP:	
			December 2, 2003		
	1 2000		2000111001 2, 2003		
70	2000.	at all IICa dias Tourand a Complesia	FEnethilana A. Stangar	antrolled Assembly of the	
١		o, et al., "Studies Toward a Synthesis of			
		on and Models for Macrocyclization", al., "Metabolic Diversity in Myxobac			
	195, 1999				
	*Biswas, et al., Highly Concise Routes to Epothilones: The Totel Synthesis and Evaluation				
		e 490, J. Am. Chem. Soc., 124: 9825-9			
]		al., "In vivo Metabolism of Epothilon			
		New Epothilone B Metabolites by Cap			
		etry/Tandem Mass Spectrometry" Rap			
		al., Protracted Low-Dose Effects on I			
 	1	eveal a Selective Antiangiogenic Win	dow for Various Chemot	nerapeutic Drugs	
		esearch, 62: 6938-6943, 2002.	and ITadaslasia Ass Ca	talamed has the Tecleted	
		t al., Epothilone C. Macrolactonizatio			
		se Domain of Epothilone Polyketide S			
	Cycloaddi	al., "Stereoselective Syntheses of Epo	uniones A and B via Dii	scied Millie Oxide	
	1 7	em. Soc., 123 (15): 3611-3612, 2001.		•	
		al., Stereoselective Syntheses of Epotl	nilones A and B via Nitri	le Oxide Cycloadditions	
.	1	ed Studies" J. Org. Chem., 66(19): 641		ic Oxide Cycloadditions	
	*Bornsche	euer, et al., "Directed Evolution of an l	Esterase for the Stereosel	ective Resolution of a	
	Key Intern	nediate in the Synthesis of Epothilone	s", Biotechnol. Bioeng.,	58 (5): 554-559, 1998.	
	*Borziller	i, et al., "A Novel Application of a Pd	(0)-Catalyzed Nucleophi	lic Substitution Reaction	
	to the Reg	io and Stereoselective Synthesis of La	ctam Analogues of the E	pothilone Natural	
	Products"				
		em. Soc., 122(37): 8890-8897, 2000.			
		t al., Late Activation of Apoptotic Pat			
	1 7	Effects of Discodermolide and Epothi	lone B in Non-Small Ce	ll Lung Cancer Cells	
		search, 62: 4081-4088, 2002.			
		nd, et al "A Novel Application of a P			
		io- and Stereoselective Synthesis of L	actam Analogues of the	Epothilone Natural	
	Products"				
		s, 14(7): 401-404, 2001.	. 1 1 0, 131 2 4		
		al., "Epothilones: A New Class of Mic		enis with a Taxoi-Like	
		n of Action, Chemtracts, 11: 671-677		one A Dayed to Dubulin	
		gno, et al., "The High-Resolution Solu			
	1	standing of the Structure-Activity Rela	-	Class of Antifullion	
	Agents" A	ngew.Chem.Int.Ed., 42: 2511-2515, 20	udes from Ch Ch Dingla	r Dinolar Cross	
	Carioma	gno, et al., "Derivation of Dihedral An Relaxation Rates: A C-C Torsion Inv	igies nom en-en Dipola	hon Atom in Fnothilane A	
	1		-	non vioui in Ehomitone W	
	Bound to Tubulin" Angew. Chem. Int. Ed., 42: 2515-2517, 2003. *Carreira, E., "Discovery and Study of New Reaction Chemistry: Applications in Complex				
				ations in Complex	
N/	Molecule Assembly" <i>Chimia</i> , 55(10): 818-820, 2001.				

FORM PTO	U.S. Department of Commerc	e ATTY. DOCKET:	IN RE		
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:		
		(SK-744-CON9)	10/726,386		
INFORMAT	ION DISCLOSURE STATEMENT	APPLICANT: Danishe	fsky et al		
(Use s	everal sheets if necessary)	FILING DATE:	GROUP:		
		December 2, 2003			
VO	*Casas, et al BINOLAM, a Recoverable Chin	ral Ligand for Bifunctional	Enantioselective		
70	Catalysis: The Asymmetric Synthesis of Cyan	ohydrins Organic Letters,	(15): 2589-2592, 2002.		
1	*Chappell, et al., "En Route to a Plant Scale S	·	Antitumor Agent 12,13-		
	Desoxyepothilone B" Org. Letter. 2(11): 163	3-1636, 2000.	Jacobayy Starter Unit on		
	*Chen, et al "Epothilone Biosynthesis: Assethe EpoB Subunit" Chem. Biol., 8(9): 899-912		icarboxy Starter Offit off		
	*Chevalier, Epothilones: A New Generation of	of Microtubule-Stabilizing (Compounds, 13-14.		
	*Chou, Desoxyepothilone B is curative agains	· · · · · · · · · · · · · · · · · · ·			
	paclitaxel Proc. Natl. Acad. Sci,95: 15798-158		nat are remactory to		
	*Chou, et al., "The Synthesis, Discovery, and	Development of a Highly F	Promising Class of		
	Microtubule Stabilization Agents: Curative E	ffects of Desoxyepothilone	s B and F Against Huma		
	Tumor Xenografts in Nude Mice" Proc. Natl. Acad. Sci., 98(14): 8113/8118, 2001.				
	*Chou, et al., "Desoxyepothilone B: An Efficacious Microtubule-Targeted Antitumor Agent with Promising In Vivo Profile Relative to Epothione B", Proc. Natl. Acad Sci., 95: 9642, 1998.				
_					
	*Chou, et al Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B <i>Proc. Natl. Acad. Sci.</i> 95: 9642-9647, 1998.				
	*Claus, E. et al., "Synthesis of the C1-C9 Seg				
	38:8:1359-1362 (1997)				
	*Corey, et al., "Chemistry of Diimide. Some I	New Systems for the Hydro	genation of Multiple		
	Bonds" Tetrahedron Lett. 347-352 1961.	Whylin Interacting Antimit	otio Drugo" Curr Pharm		
	*Correia, et al., "Physiochemical Aspects of T Des., 7(13): 1213-1228, 2001.	dounn-interacting Antimite	one Diugs Curr. Fharm		
	*Cowden, et al., "Cancer Drugs-Better than To	axol? Nature, 387: 238-239	, 1997.		
	*Danishefsky, et al, "Insights into Long-Ran				
	Condensations: A Practical Total Synthesis of		,		
	J. Am. Chem. Soc., 123(22): 5249-5259, 2001				
	*Danishefsky, et al., "On the Interactivity of C	Complex Synthesis and Tun	nor Pharmacology in the		
	Drug Discovery Process: Total Synthesis and		uations of the 15-Aza		
	Epothilones" J. Org. Chem., 66(12): 4369-437 *Danishefsky et al., "Chemical Synthesis and	8, 2001. Riological Studies of the F	nothilones-Microtubule		
	Stabilizing Agents with Enhanced Activity Agents				
	Chem. 21st Century, Ed. Keinan, Wiley-VCH	_			
	*Danishefsky, et al., "En Route to a Plant Sca	le Synthesis of the Promisir	ng Antitumor Agent		
	12,13- Desocyepothilone B" Org. Letters, 2: 1	633-1636, 2000.	T		
	*Danishefsky, et al., "On the Total Synthesis				
	15 (S) Aza-dEpoB: A Mitsunobu Inversion at 1637-1639, 2000.	C13 in Pre-Epointione Praj	gments Org. Letters, 2:		
	*Danishefsky, et al., "The Total Synthesis and	Antitumor Activity of 12.	13-Desoxyepothilone F:		
	An Unexpected Solvolysis Problem at C15, M.				
	Chem., 65(20): 6525-6533, 2000.				
	*Danishefsky, et al "Subtle Variations in the	Long Range Transmission	of Stereochemical		

FORM P	TO-1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE			
(REV. 8-	83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:			
			(SK-744-CON9)	10/726,386			
		CLOSURE STATEMENT	APPLICANT: Danishe	fsky <i>et al</i>			
(L	Ise several shee	ets if necessary)	FILING DATE:	GROUP:			
			December 2, 2003				
Yo							
	Epothilon	*Danishefsky, et al., "Dianion Equivalents Corresponding to the Polypropionate Domain of Epothilone B" <i>Tetrahedron Letters</i> , 40: 2263-2266, 1999.					
	Condensa	sky, et al., "Remarkable Long Range lition" <i>Tetrahedron Letters</i> , 40 : 2267-22	270, 1999.				
	*Danishef	sky, et al., "The microtubule-stabilizing	ng agents epothilones A a	and B and their desoxy-			
		s induce mitotic arrest and apoptosis in	n human prostate cancer	cells." Prostate Cancer			
	*Donished	atic Diseases, 2: 41-52, 1999. Sky, "New Chemical synthesis of the	Promising Cancer Cheme	otheraneutic Agent 12 13-			
	Desorven	othilone B: Discovery of a Surprising	Long-Range Effect on th	e Diastereoselective of an			
		idensation." J. Am. Chem. Soc., 121: 7					
	*Danishef	*Danishefsky, et al., "A Novel Aldol Condensation with 2-Methyl-4-Pentenal and the Application					
	to an Impr	to an Improved Total Synthesis of Epothilone B", Angew. Chem. Int. Ed. 37: 2675, 1998.					
· [*Danishef	*Danishefsky, et al., "Epothilones: Microtubule Stabilizing Agents with Enhanced Activity					
		Against Multidrug-Resistant Cell Lines and Tumors." Actualites de Chimie Therpaeutique, Vingt-					
		cinqueme serie, Paul Ehrlich Lecture, Societe de Chimie Therapeutique, Elsevier, Paris, New York, 25: 187-206, 1999.					
		*Danishefsky, et al., "The Synthesis and Evaluation of 12,13-Benzodesoxyepothilone B: a Highly					
		Convergent Route." Tetrahedron Letters, 40: 6895-6898, 1999.					
	*Danishef	sky, et al., "Complex Target Oriented	lex Target Oriented Synthesis in the Drug Discovery Process: A Case				
	History in	the dEpoB Series" J. Org. Chem., 64:	8434-8456, 1999.				
ļ		*Danishefsky, et al., "Desoxyepothilone B is Curative Against Human Tumor Xenografts that are					
		Refractory to Pacilitaxel", Proc. Nat. Acad. Sci., 95: 15798, 1998.					
	Metathesis	*Danishefsky, et al., "Remote Effects in Macrolide Formation Through Ring Forming Olefin Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners", J. Am. Chem. Soc. 119: 2733, 1997.					
	*Danishef Method ar	*Danishefsky, et al., "Total Synthesis of (-) - Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure - Activity Relationships of the Epothilones", Angew. Chem. Int. Ed. 36: 757, 1997.					
	*Danishef Compariso	*Danishefsky, et al., "Structure-Activity Relationships of the Epothilones and the First in Vivo Comparison with Paclitaxel", Angew. Chem. Int. Ed., 7: 824-826, 1997.					
	and C(7)-0	ander, et al., "Towards a Synthesis of I C(12) Fragments", <i>Synlett</i> , 7: 824-826	, 1997.	·			
	*De Braba	ander, et al., "Towards a Synthesis of I	Epothilone A", Synlett, 3:	328, 1998.			
	*	ander, et al., "Towards a Synthesis of l C(12) Fragments" <i>Synlett</i> , 6: 692, 1998		embly of the C(1)-C(6)			
	*Delbaldo 802-809, 2	, et al., Nouveaux medicamenets dans 2002.	le cancer bronchique La				
	*Denmark Complexe	*Denmark, et al., "Cyclopropanation with Diazomethane and Bis(Oxazoline) Palladium(II) Complexes", J. Org. Chem. 62:3375-3389, 1997.					
$\overline{}$, et al., "Enantioselective Aldol Reacti rate Complexes", Angew. Chem. Int. 1					

FORM PTO	•		IN RE APPLICATION NO.:			
(REV. 8-83)	Patent and Trademark Office	2003080-0143 (SK-744-CON9)	10/726,386			
INFORMA'	ΓΙΟΝ DISCLOSURE STATEMENT	APPLICANT: Danishet				
	several sheets if necessary)	FILING DATE:	GROUP:			
(,	December 2, 2003	GROUP:			
	*End, et al., "Synthetic Epothilone Analogs		orthern Hemisphere and			
$\forall o$	the Heterocyclic Side-Chain-Synthesis and I		<u> </u>			
{	ECSOC-4, 1999, 2000, Meeting Date 1999-2	•				
	Molecular Diversity Preservation Internation					
	*Essayan, et al., "Successful Parenteral Dese 97: 42-46, 1996.					
	*Finley, et al., "Metathesis vs. Metastasis: T Ind. 24: 991-996, 1997.					
	*Florsheimer, et al., "Epothilones and Their Inhibitors"	_	romising Microtubule			
	Expert Opin. Ther. Pat., 11(6): 951-968, 200	l.	a via Madulation after			
	*Frykman, et al., Control of Secondary Metabolite Congener Distributions via Modulation of the					
	Dissolved Oxygen Tension, <i>Biotechnol. Prog.</i> , 18: 913-920, 2002. *Fürstner, "Olefin Metathesis and Beyond", <i>Angew. Chem. Int. Ed. Engl.</i> 39: 3013-3043, 2000.					
	*Furstner, et al., "Concise Total Syntheses of Epothilone A and C Based on Alkyne Metathesis"					
	Chem. Commun., 12: 1057-1059, 2001.					
	*Geng, et al., "Design and Synthesis of De Novo Macrocyclic Hybrids as Potential Anticancer					
	Agents" Abstr. PapAm. Chem. Soc., 221st, MEDI-130, 2001					
	*Georg, et al, "Studies Toward the Synthesis of Epothilone Affinity Labels" Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, MEDI-075, 2000.					
	*Gerlach, et al., "Synthesis of the C(7)-C(17) Segment of Epothilones by a 10-Membered Ring Closing Metathesis Reaction", Synlett, 10: 1108-1110, 1998					
	*Gerth, et al., "Studies on the Biosynthesis of Epothilones: the PKS and Epothilone C/D Monooxygenase" J. Antibiot., 54(2): 144-148, 2001.					
	*Gerth, et al, "Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangium cellulosum (Myxobacteria) Production, Physico-chemical and Biological Properties, <i>The Journal of Antibiotics</i> , 49-53, 1996.					
	*Gerth, et al., "Studies on the Biosynthesis of Epothilones: The Biosynthetic Origin of the Carbon Skeleton" J. Antibiot, 53(12): 1373-1377, 2000					
	*Giannakakou, et al., "A Common Pharmace Basis for Drug Resistance Conferred by Tub Acad. Sci., 97(6): 2904-2909, 2000.	ulin Mutations in Human Car	ncer Cells" Proc. Natl.			
	*Griffin, et al., Molecular Determinants of Epothilone B Derivative (BMS 247550) and Apo- 2L/TRAIL-induced Apoptosis of Human Ovarian Cancer Cells, <i>Gynecologic Oncology</i> , 89 : 37-47, 2003.					
	*Grubbs, et al., "Ring-Closing Metathesis an Res. 28: 446-452, 1995.	d Related Processes in Organ	nic Synthesis" Acc. Chem			
	*Gupta, et al., Understanding Tubulin-Taxol Yeast Tubulin PNAS, 100: 5394-6397, 2003.		Impart Taxol Binding to			
	*Hamashima, et al., "Highly Enantioselectiv Acid-Lewis Base Bifunctional Catalyst" Teta					

FORM PTO	-1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:	
		(SK-744-CON9)	10/726,386	
	ION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al		
(Use s	several sheets if necessary)	FILING DATE:	GROUP:	
		December 2, 2003		
70	*Hardt, et al., "New Natural Epothilones from S ce90/D13: Isolation, Structure Elucidation and S			
	*Harris, et al., Complex Target-Oriented Syntherin the dEpoB Series J. Org. Chem., 64: 9434-845	•	Process: A Case History	
	*Harris, et al., New Chemical Synthesis of the P. Desoxyepothilone B: Discovery of a Surprising an Aldol Condensation J. Am. Chem. Soc., 121: *Hayward, et al. "Total Synthesis of Rapamycin	Long-Range Effect on the 7050-7062, 1999.	Diastereoselectivity of	
ł	Macrocyclization Reaction", J. Am. Chem. Soc.,			
	*He, et al., Novel Molcules that Interact with Mi Taxol Elsevier Science Ltd. DDT, 6: 1153-1164,		tional Activity Similar to	
	*He, et al "Novel Molecules that Interact with I to Taxol" <i>Drug Discovery Today</i> , 6(22): 1153-11		nctional Activity Simila	
	sed on the Biological 39(14): 3972-3978,			
	*He, Yun et al., "Total Synthesis and Biological Institute Order No.: DA9966202 From: Diss. A	Abstr. Int., B 2000, 61(3),	1414, 2000	
	*Hindpur, et al., "Total Synthesis of Epothilone	A" Tetrahedron Letters, 4	2 (42): 7341-7344, 2001	
	*Hofle, et al., "Epothilone A-D and Their Thiazo Agents, Pure Appl. Chem., 71: 2019-2024, 1999.	•		
	*Holland, M., "1. The Synthesis of a Cyclopropy Reactions. 2. The Design and Synthesis of Nove Pennsylvania <i>Order No.</i> : DA9953544 From: D	el Epothilone Analogs" U	niversity of	
V	*Holland, et al., "Design, Synthesis and Biologic Abstracts, 215th ACS National Meeting, Dallas,	cal Evaluation of Epothilo	ne Analogs", Book of	
40	*Hosle, et al., Epothilone A and B – Novel 16-Me Isolation, Crystal Structure, and Conformation in 1569, 1996.		Cytotoxic Activity:	
	*Hofle, et al., "N-Oxidation of Epothilone A-C a Substituted Epothilones" Angew. Chem. Int. Ed.,	38(13/14): 1971-1974, 19	999.	
_	*Inoue, et al., "Design and Synthesis of Taxoid-l ACS National Meeting, Boston, August 23-27, C	ORGN-380. No	year	
10	*Ivin, "Some Recent Applications of Olefin Met Catal. A: Chem, 133(1-2): 1998			
	*Jaenicke, L., "Epothilone from Amphora" Cher	n. Unserer Zeit (German)	, 34(4): 257, 2000.	
	*Jiang, et al., "Advances in Research on Novel Epothilones" Tianran Chanwu Yanjiu Yu Kaifa (

FORM PTO	U.S. Department of Commerc	ATTY. DOCKET:	IN RE			
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:			
		(SK-744-CON9)	10/726,386			
	TION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al				
(Use	several sheets if necessary)	FILING DATE:	GROUP:			
		December 2, 2003				
70	*Johnson, et al "Synthesis, Structure Proof, a	and Biological Activity of E	Epothilone			
	Cyclopropanes" Org. Lett, 2: 1537-1540, 2000					
	*Julien, et al., "Isolation and Characterization		netic Gene Cluster from			
	Sorangium Cellulosum" Gene, 249(1-2): 153-		na Cham 11: 2817			
	*Kalesse, et al., "The Formal Total Synthesis 2823, 1999.	of Epotimone A Eur. J. O.	18. Chem., 11. 2017-			
	*Klar, et al., "Epothilones" Book of Abstracts	. 219th ACS National Meet	ing, San Francisco, CA,			
	March 26-30, ORGN-288, 2000.					
	*Koch, et al., Diastereoselective Titanium End		Total Synthesis of			
	Epothilones Organic Letters, 2(22): 3811-381	4, 2002.	0 1 1 1 1 7 1			
	*Krische, et al., "Diastereoselective Cobalt-C	atalyzed Aldol and Michael	Cycloreductions" J. Am.			
 	Chem. Soc. 123: 5112-5113, 2001.	one Analog with a Mode of	Action Similar to			
\	Paclitaxel but Possessing Superior Antitumor	*Lee, et al., "BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy" Clin. Cancer Res., 7(5): 1429-1437, 2001.				
	*Lee, et al., "Synthesis of the C11-C21 and C13-C21 Fragments of Epothilones from D-glucose"					
	Bull. Korean Chem. Soc., 21(12): 1177-1178, 2000.					
	*Lee, et al., "Synthesis Toward Epothilone A: A Coupling Reaction Between the Sulfone of C1-					
	C10 and the Allylic Bromide of C11-C21" Bull. Korean Chem. Soc., 20(4): 403-404, 1999.					
	*Lee, et al., "Insights into Long-Range Structural Effects on the Stereochemistry of Aldol Condensations: A Practical Total Synthesis of Deoxyepothilone F" J. Am. Chem. Soc. 123: 5249-					
	5259, 2001.					
	*Lee, et al., "Total Synthesis and Antitumor Activity of 12,13-Desoxyepothilone F: An					
	Unexpected Solvolysis Problem at C15, Mediated by Remote Substitution at C21" J. Org. Chem.,					
	65: 6525-6533, 2000.					
	*Li, et al., "Synthesis of a Novel Epothilone B Analog as a Potential Photoaffinity Label" Abstr.					
	PapAm. Chem. Soc. 221 st , MEDI-137, 2001 *Li, et al., "Process Development of the Semisynthesis of a Biologically Active Epothilone					
	Analogue"					
	Abstracts of Papers, 222 nd ACS National Meeting, Chicago, IL, August 26-30, ORGN-238, 2001.					
	*Li, et al., "Antimitotic Agents" Annu. Rep. Med. Chem., 34: 139-148, 1999,					
	*Lichtner, et al., "Subcellular Distribution of		nor Cells" Proc. Natl.			
	Acad. Sci. U.S.A., 98(20): 11743-11748, 2001		1 1 0			
	*Lin, et al., "Design, Synthesis and SAR of N	ovel Hybrid Constructs Bas	sed on the Common			
	Pharmacophore for Microtubule-Stabilizing Agents" Book of Abstracts, 217th ACS National meeting, Anaheim, CA, March 21-25, MEDI-038, 1999.					
	*Lin. et al., "Design and Synthesis of Taxoid-		of Abstracts, 216th ACS			
	National Meeting, Boston, August 23-27, OR	GN-464. NO Yel	μ <u> </u>			
√p	*List, et al., "Proline-Catalyzed Direct Asymi	netric Aldol Réactions" J .	Am. Chem. Soc. 122:			
10	2395-2396, 2000.					
	*Liu, et al., Total Synthesi of Epothilone A th	rough Stereospecific Epoxi	idation of the p-			
	Methoxybenzyl Ether of Epothilone C Chem.	Eur. J., 8(16): 3747-3756, 2	2002.			
,1/	*Liu, et al., "Epoxide Opening with Acetylide	for Synthesis of Epothilon	e A C7-21 Segment",			

FORM PT	•		IN RE			
(REV. 8-83) Patent and Trademark Office		2003080-0143	APPLICATION NO.:			
		(SK-744-CON9)	10/726,386			
	TION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al				
(Use	several sheets if necessary)	FILING DATE:	GROUP:			
		December 2, 2003				
-16	Tetrahedron Lett. 39(29): 5261-5264, 1998.					
	*Liu, et al., "Synthesis of the C11-16+C27 Se 38, 1998.	gment of Epothilone A", (Chin. Chem. Lett.9(1): 35-			
	*Machajewski, et al., "Chemoenzymic Synthe Iss.), 1469-1472, 1999.					
	*Martin, et al., Marshall, "Total Synthesis of I	Epothilone", Nat. Biotechn	ol. 15 (3): 205, 1997.			
	*Martin, et al "The 12,13-diol Cyclization A of Epothilone B and the Synthesis of a Confor Chem. Eur. J, 42(47): 8373-8377, 2001	mationally Restrained An	alog"			
	*Martin, "How Stable are Epoxides? A Nove ,39(3): 581-583, 2000.					
	*May, et al., "Total Synthesis of (-) Epothilon					
	*McDaid, et al., Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, During a Phase I Clinical Study, <i>Clinical Cancer Research</i> , 8: 2035-2043, 2002.					
	*Meng, Dongfang, et al., "Chapter I: The First Total Syntheses of Epothilones A, B, C and D. Chapter II: The First Total Syntheses of 12-epi-CP-263,114 and 12-epi-CP-225,917" Columbia University					
	Order No.: DA9949022 From: Diss. Abstr. Int., B2000, 60(10), 5096 (1999)					
	*Molnar, et al., "The Biosynthetic Gene Cluster for the Microtubule-Stabilizing Agents					
	Epothilones A and B from Sorangium Cellulosum So ce90" Chem. Biol., 7(2): 97-109, 2000. *Mulzer, et al., "Epothilone B and its Derivatives as Novel Antitumor Drugs: Total and Partial					
	Synthesis and Biological Evaluation" <i>Monatsh. Chem.</i> , 131(3): 205-238, 2000.					
	*Mulzer, et al., "Total Syntheses of Epothilones B and D" J. Org. Chem., 65(22); 7456-7467,					
	2000.					
.	*Mulzer, et al., "A Novel Highly Stereoselective Total Synthesis of Epothilone B and of its					
	(12R,13R) Acetonide" Tetrahedron Lett, 41(40): 7635-7638, 2000 *Mulzer, et al., "Synthesis of the C(11)-C(20) Segment of the Cytotoxic Macrolide Epothilone B",					
	Tetrahedron Letters", 38(44): 7725-7728, 1997.					
	*Mulzer, et al "Easy Access to the Epothilone Family-Synthesis of Epothilone B", Tetrahedron					
	Letters, 39(47): 8633-8636, 1998.					
	*Mulzer, "Progress in the Synthesis of Chiral Heterocyclic Natural Products: Epothilone B and Tartrolon B" J. Heterocycl. Chem., 36(6): 1421-1436, 1999.					
	*Nakamura, S., "Total Synthesis of Antitumor Antibiotic Epothilone Having Same Mechanism of Action with Taxol", Kagaku (Kyoto)", (In Japanese) 52(7): 70-71, 1997.					
1	*Newman, et al., "Antitumor Efficacy of 26-Fluoroepothilone B Against Human Prostate Cancer Xenografts" Cancer Chemother. Pharmacol., 48(4): 319-326, 2001.					
	*Nicolaou, et al., Recent Developments in the Epothilones		Medicine of the			
	Chem. Commun., 1523-1535, 2001.					
	*Nicolaou, et al., "Synthesis and Biological E cyclobutyl Epothilones"	valuation of 12, 13-cyclop	propyl and 12,13-			
$\sim 1/$	ChemBioChem (Angew. Chem. Int. Ed. Engl.)	, 2 (1): 69-75, 2001.				

FORM PT	•	rtment of Commerce	ATTY. DOCKET:	IN RE			
(REV. 8-83) Patent and Trademark		Trademark Office	2003080-0143	APPLICATION NO.:			
			(SK-744-CON9)	10/726,386			
	TION DISCLOSURE STA	TEMENT	APPLICANT: Danishefsky et al				
(Use	several sheets if necessary)		FILING DATE:	GROUP:			
			December 2, 2003				
YD	*Nicolaou, et al., "Recent			ledicine of the			
10	Epothilones"Chem. Comm	un., 17: 1523-1535, 2	001.				
ſ	*Nicolaou, et al "Chemic	al Synthesis and Biol	ogical Evaluation of cis- a	and trans-12,13-			
	cyclopropyl and 12,13-cyc Chem. Soc., 123(38): 9313		na Related Pyriaine Side	Chain Analogues J. Am.			
	*Nicolaou, et al., "Synthes	sis of 16-desmethylen	othilone B: Improved Me	thodology for the Rapid,			
	Highly Selective and Converse 519-520, 1999.	vergent Construction of	of Epothilone B and Analo	ogs" Chem. Commun., 6:			
	*Nicolaou, et al., "Total S						
1	and Related Side Chain M	odified Epothilone B	Analogues", Chem. Eur. J	7., 6(15): 2783-2800,			
	2000.	-10 -4 - ' 1D'-1	- i - I D i C D i d	na Enathilanaell Cham			
	*Nicolaou, et al., "Chemic	al Synthesis and Biol	ogical Properties of Pyridi	ne Epointiones Chem.			
		Biol. 7(8): 593-599, 2000. *Nicolaou, et al., "Chemistry, Biology and Medicine of Selected Tubulin Polymerizing Agents"					
	Pure Appl. Chem., 71(6): 989-997, 1999.						
	*Nicolaou, K.C. et al. "Synthesis and Biological Properties of C12,13-Cyclopropyl-Epothilone A						
	and Related Epothilones" Chem. Biol, 5(7): 365-372, 1998.						
	*Nicolaou, et al., "Total Synthesis of Epothilone E and Related Side-Chain Modified Analogues						
	via a Stille Coupling Based Strategy" Bioorg. Med. Chem., 7(5): 665-697, 1999.						
	*Nicolaou, et al., Chemie und Biologie der Epothilone, Agnew. Chem., 110: 2120-2153, 1998.						
	*Nicolaou, et al., "Probing the Ring Size of Epothilone: Total Synthesis of [14]-, [15]-,[17]-," Angew. Chem. Int. Ed, 37: 81-87, 1998						
	*Nicolaou, et al., "Total Synthesis of Epothilone E and Analogues with Modified Side Chains						
	through the Stille Coupling Reaction" Angew. Chem. Int. Ed., 110: 85-92, 1998. *Nicolaou, et al., Intellectual Screening of Natural Products for Drugs", Farumashia, 33(12):						
:	1339-1345, 1997.						
	*Nicolaou, K.C. et al., "Total Synthesis of 26-hydroxyepothilone B and related analogues", Chem. Commun. 2343-2344 (1997)						
	*Nicolaou, et al., "Chemic 1998.						
	*Nicolaou, et al., "Ring-Closing Metathesis in the Synthesis of Epothilones and Polyether Natural						
	Products" Top. Organome						
	*Nicolaou, et al., "The Old		oach to Epothilone A and	its Analogs", J. Am.			
	*Nicolaou, et al., Synthesi		nd B in Solid and Solution	Phase", Nature 387			
	268-272, 1997.	o or Eponinones. A ai	ic 5 in cona ana conanor				
	*Nicolaou, et al., "Synthesis of Epothilones: A and B in Solid and Solution Phase", Nature, 390: 100, 1997.						
	*Njaardarson, et al., Appl	cation of hitherto une	xplored macrocyclization	strategies in the			
	epothilone series: novel ep	othilone analogs by to	otal synthesis, Chem. Con	nmun., 2759-2761, 2002.			
	*Ojima, et al., "New-Gend	eration Taxoids and H	ybrids of Microtubule-Sta	bilizing Anticancer			
	Agents" Book of Abstracts	, 219 th ACS National	Meeting, San Francisco, (CA, March 26-30,			
V	ORGN-245, 2000.						

FORM PTO	1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)		Patent and Trademark Office	2003080-0143 (SK-744-CON9)	APPLICATION NO.: 10/726,386	
INFORMAT	ION DISC	CLOSURE STATEMENT	APPLICANT: Danishefsky et al		
(Use s	everal shee	ets if necessary)	FILING DATE:	GROUP:	
·			December 2, 2003	GROOT.	
40		t al., "A Common Pharamcophore for ales Proc. Natl. Acad. Sci. U.S.A., 96:		icts that Stabilize	
	*Panicker Enantiose 7868, 200	, et al An unusual Reversal of Stereo lective Synthesis of the C1-C6 Segme 0.	selectivity in a Boron M nt of the Epothilones" To	etrahedron, 5 6(40): 7859-	
	Cell Perm	, et al., "The Role of the Microtubules leability" <i>Am.J.Respir.Cell Mol.Biol.</i> , 2	28 : 574-581, 2003.		
	Sorangiur	et al Characterisation, Genome Size n Cellulosum So ce56, Archives of Mic	crobiology, 1-17, 2002.		
·	Kills Cell Activity I	al., The Microtubule Stabilizing Agens Resistant to Paclitaxel and Epothilon Biochemistry, 41: 9109-9115, 2002.	es, and May Not Requir	e Its Epoxide Moiety for	
	*Quitschalle, et al., "Improved Synthesis of the Northern Hemisphere of Epothilone A by a Sharpless Asymmetric Dihydroxylation" <i>Tetrahedron Letters.</i> , 40(44): 7765-7768, 1999.				
	*Regentin, et al., "Development of a Cost Effective Epothilone D Process in Myxococcus Xanthus" Abstr. Pap-Am. Chem. Soc. 221 st , BIOT-061, 2001.				
	*Regentin, et al., Nutrient Regulation of Epothilone Biosynthesis in Heterologous and Native Production Strains Appl Microbiol Biotechnol, 61: 451-455, 2003.				
	*Regueiro-Ren, et al., "Synthesis and Biological Activity of Novel Epothilone Aziridines" Org. Lett., 3(17): 2693-2696, 2001.				
	*Regueiro	o-Ren, et al., SAR and pH Stability of (15-3818, 2002.			
	*Reiff, et ACS Nati	al., "Progress Toward Total Syntheses onal Meeting, Dallas, March 29 April	2, ORGN-086 No	Year	
40	*Rivkin, et al., Complex Target-Oriented Total Synthesis in the Drug Discovery Process: The Discovery of a Highly Promising Family of Second Generation Epothilones, J. Am. Chem. Soc, 125: 2899-2901, 2003.				
	*Rivkin, et al., Total Syntheses of [17]- and [18] Dehydrodesoxyepothilones B via a Consise Ring Closing Metathesis-Based Strategy: Correlation of Ring Size with Biological Activity in the Epothilone Series J. Org. Chem., 67: 7737-7740, 2002.				
	*Rivkin, Chemical Organic	et al., On the Introduction of a Trifluo Issues Related to Ring Forming Olefin Letters, 4(23): 4081-4084, 2002.	romethyl Substituent in Metathesis and Earlies	t Biological Findings	
	*Santi, et al., "An Approach for Obtaining Perfect Hybridization Probes for Unknown Polyketide Synthase Genes: A Search for the Epothilone Gene Cluster" Gene, 247(1-2): 97-102, 2000.				
	*Sawada, et al., "Enantioselective Total Synthesis of Epothilone A Using Multifunctional Asymmetric Catalysis" Angew. Chem. Int. Ed., 39(1): 209-213, 2000.				
	*Sawada, Asymmet	et al., "Enantioselective Total Syntheric Catalysis" J. Am. Chem. Soc., 122(sis of Epothilones A and 43): 10521-10532, 2000	·	
In complete	*Schrock	, Olefin Metathesis by Well-Defined C	Complexes of Molybden	um and Tungsten.	
10	*Sefkow,	et al., "Derivatization of the C12-C13 Med. Chem., 8: 3031-3036, 1998.	Functional Groups of E	pothilones A, B, and C,	

FORM PTO	1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE		
(REV. 8-83) Patent and Trademark Office		2003080-0143	APPLICATION NO.:		
(142 . 1 0 02)	2	(SK-744-CON9)	10/726,386		
INFORMAT	ION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al			
(Use s	everal sheets if necessary)	FILING DATE:	GROUP:		
,	•	December 2, 2003	okoor.		
. (0	+0.0	<u> </u>	A" Pipora Mad		
40	*Sefkow, et al., "Oxidative and Reductive Tran Chem.8(21): 3025-3030, 1998.				
	*Sefkow, et al., "Substitutions at the Thiazole N 2488, 1998.				
	*Schinzer, et al., "Total Synthesis of (-)-epothil	one A" <i>ChemEur. J.</i> , 5(9)): 2483-2491, 1999.		
	*Schinzer, et al., "Total Synthesis of (-)-epothil	one B" ChemEur. J., 5(9)	: 2492-2500, 1999.		
	*Schinzer, et al "Synthesis and Biological Eva Ed. ChemBiochem, 1(1): 67-70, 2000.	·			
	*Schinzer, et al., "Synthesis of Epothilones. Ste 861-864, 1998.				
	*Schinzer, Interview: Epothilones-New Promis		g Products with Taxol-		
	like Biological Activity, ECC Braunschewig	Incomplete	1.2 5 // /		
Va	*Schinzer, et al., "New and Convenient Synthes	sis of ® and (8) of 2-methy	1-3-oxa-5-(tert-		
$l \cup l$	butyldiphenylsilyloxy)methylpentanoate and 2-methyl-3-oxa-5-(tert-butyldimethylsiloxy)methylpentanoate" <i>Phosphorus, Sulfur Silicon Relat. Elem.</i> , 158 : 187-199,				
1	2000.	orus, buljur bitteon Retail Diem., 136. 107 155,			
		rates by the First Three Modules of the Epothilone			
1	Synthetase Assembly Line J. Am. Chem. Soc., 1	24: 11272-11273, 2002. esis Activity of Ruthenium-Based Olefin			
	*Scholl, et al., "Increased Ring Closing Metathe				
	Metathesis Catalysts Coordinated with Imidazo 1999.				
	*Scudiero, et al., Evaluation of a Soluble Tetraz Sensitivity in Culture Using Human and Other 4833, 1988.	olium/Formazan Assay for Formation Cell Lines, Cancer	r Cell Growth and Drug Research, 48: 4827-		
·	*Shibasaki, et al., "Multifunctional Asymmetric 2001.				
	*Shioji, et al., "Synthesis of C1-C6 Fragment for Resolution" Synth. Commun., 31(23): 3569-357	75, 2001 .			
	*Sinha, et al., "The Antibody Catalysis Route to Acad. Sci95(25): 14603-14608, 1998.	o the Total Synthesis of Ep			
$\overline{}$	*Sinha, et al., "Catalytic Antibody Route to the of Epothilones A-F" Chem. Eur. J., 7(8): 1691-	702, 2001.			
	*Sinha, et al "Total Synthesis of Epothilones	and Some 14-Flouroanalog	s via Antibody		
•	Catalysis"	No year	he onewasa		
	Book of Abstracts, 217th ACS National Meeting	, Anaheim, CA, March / I-	1 Paralytian of Thiazale		
$\sqrt{\circ}$	*Sinha, et al., "Synthesis of Epothilone Analog Aldol Synthons on a Multigram Scale. Biologi Epothilones" ChemBioChem, 2(9): 656-665, 20	cal Consequences of C-13	Alkylation of		
	*Sinha, et al., "Sets of Aldolase Antibodies wit	h Antipodal Reactivities.	Formal Synthesis of		
	Epothilone E by Large Scale Antibody-Catalyz 1623-1626, 1999.	ed Resolution of Thiazole	Aldol" Org. Lett., 1(10):		
	*Sinha, et al., "Regioselective Synthesis of Flu	oro Aldols. Studies Toward	d Fluro Epothilones		
V	J, J, 1.05.00010011.10 07.110		<u> </u>		

FORM PTC	0-1449 U.S. Department of Commerce	e ATTY. DOCKET:	IN RE			
(REV. 8-83)	•	2003080-0143	APPLICATION NO.:			
(,		(SK-744-CON9)	10/726,386			
INFORMA?	TION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al				
(Use	several sheets if necessary)	FILING DATE:	GROUP:			
		December 2, 2003				
70	Syntheses via Antibody Catalysis" Tetrahedro		46. 2000.			
	*Skehan, et al., New Colorimetric Cytotoxicit					
1	the National Cancer Institute, 82: 1107-1112,	1990.				
	*Smart, Fluorine Substituent Effects (on bioac 2001.					
	*Stachel, et al., "The Epothilones, Eleutherob Des., 7(13): 1277-1290, 2001.					
	*Stachel, et al., "Chemo- and Stereoselective 2,2'-dimethyldioxirane" Tetrahedron Lett., 42		xyepothilone B using			
	*Still, et al., "Stereoselective Synthesis of 1,3 of Rifamycin S" J. Am. Chem. Soc. 105: 2487	-Diol Derivatives and Appl	ication to the Ansa Bridge			
	*Su, et al., Structure – Activity Relationships with Paclitaxel Angew. Chem. Int. Ed. Engl.3	of the Epothilones and the	First In Vivo Comparison			
	*Tamao, et al., "Selective Carbon-Carbon Bo	nd Formation by Cross-Cou	pling of Grignard			
	Reagents with Organic Halides. Catalysis by 1 4374-4379, 1972.	Nickel-Phospine Complexe	s" J. Am. Chem Soc. 94:			
	*Tang, et al., "Cloning and Expression of the 2000.					
	*Tang, et al., "Generation of Novel Epothilon Biotransformation The Journal of Antibiotics,		etivity by			
	*Tanimori, et al., "Simple Synthesis of Both I Biosci. Biotechnol. Biochem, 62(12): 2428-24	Enantiomers of the C7-C12	Segment of Epothilones"			
	*Tanimori, et al., "Easy Access to Both Enan Commun., 29(24): 4353-4360, 1999.		t of Epothilones" Synth.			
	*Taylor, et al., "Total Synthesis of Epothilone	es B and D" Org. Lett., 3(14): 2221-2224, 2001.			
No lease	*Taylor, et al., "The Identification of the Biol					
40	*Taylor, et al., "The Conformational Properties 5449, 2000.	<u> </u>				
	*Taylor, et al., "Conformational Properties of 1999.	Epothilone" J. Org. Chem.	, 64(19): 7224-7228,			
	*Taylor, et al., Catalytic Diastereoselective R					
	12202-12203, 1999.					
	and C7-C12 Fragments" J. Org. Chem., 63(25)	*Taylor "A Formal Total Synthesis of Epothilone A: Enantioselective Preparation of the C1-C6 and C7-C12 Fragments" J. Org. Chem., 63(25): 9580-9583, 1998.				
	*Ter Haar, et al., "Taxanes and Other Micrott 8(5): 571-586, 1998.					
	*Trnka, et al., "The Development of L ₂ X ₂ Ru= Organometallic Success Story", Acc. Chem.		talysts: An			
V	*Trnka, et al., The Development of L2X2Ru= Organometallic Success Story Acc. Chem.Res	CHR Olefin Metathesis Ca	talysts: An			
<u>v</u>	1 - 0	·				

FORM PTO	•	1	IN RE			
(REV. 8-83) Patent and Trademark Office			APPLICATION NO.			
		(SK-744-CON9)	10/726,386			
	TION DISCLOSURE STATEMENT	APPLICANT: Danish	efsky et al			
(Use	several sheets if necessary)	FILING DATE:	GROUP:			
		December 2, 2003				
40	*Valluri, et al., "Total Synthesis of Epothil	one B" Org. Lett., 3(23): 360	07-3609, 2001.			
	*Victory, et al., "Development of an Epoth	ilone Pharmacophore" Book	of Abstracts, 215th ACS			
	National Meeting, Dallas, March 29-April		Year			
V0	*Vite, et al., "Epothilones A and B: Spring	gboards for Semisynthesis of	Promising Antimitotic			
1,0	Agents"	···· C. F. C. II	1 26 20 ODCN 286			
	Book of Abstracts, 219th ACS National Mee 2000.	enng, san Francisco, CA, Mi	Irch 20-30, OKGN-260,			
	*Von Angerer, E"Tubulin as a Target for A	Anticancer Drugs" Curr. Opi	n. Drug Discovery Dev.,			
	3(5): 575-584, 2000.					
	*Walsh, C. "Enzymatic Assembly of Hybri	id Polyketide/Nonribosomal	Peptide Natural Products"			
	Abstracts of Papers, 222nd ACS National M.					
1	*Wessjohann, et al., "Synthesis of Natural-Product-Based Compound Libraries" Curr. Opin.					
	Chem. Biol., 4: 303-309, 2000.	nothilones Natural Products	with Extraordinary			
	*Wessjohann, et al. "Synthetic Access to Epothilones-Natural Products with Extraordinary Anticancer Activity" Org. Synth. Highlights IV Ed: Schmalz, H., Wiley-VCH Verlab GmbH:					
į į	Weinheim Germany, 251-267, 2000					
	*White, et al., Total Synthesis of Epothilone B, Epothilone D and cis-and trans-9, 10-					
	Dehydroepothilone D, J. Am. Chem. Soc., 125: 3190, 2003.					
,	*White,"Total Synthesis of Epothilone B, I		ans-9,10-			
V	Dehydroepothilone D" J. Am. Chem. Soc., *White, et al., "Synthetic Approach Towar	123(23): 5407-5413, 2001.	othilone B" Rook of			
	Abstracts, 216th ACS National Meeting, Bo	ston August 23-27 ORGN-1	141 No YPAG			
<u> </u>	*White, et al., "Two Coupling Strategies for	or a Stereoselective Synthesis	s of Epothilone B" Book o			
70	Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-813, 2000.					
	*White, et al., "A Highly Stereoselective Synthesis of Epothilone B" J. Org. Chem., 64(3): 684-					
	685, 1998.					
	*White, et al., "Improved Synthesis of Epothilone B Employing Alkylation of an Alkyne for					
	Assembly of Subunits" Org. Lett., 1(9): 1431-1434, 1999.					
1	Chem. Letter, 6: 2963-2966, 1996.	*Winkler, et al., "A Model for the Taxol (Paclitaxel) Epothilone Pharmacophore", Bioorg., Med.				
	*Winkler, et al., "Design and Synthesis of Constrained Epothilone Analogs: The Efficient					
1	Synthesis of Eleven-Membered Rings by C	Synthesis of Eleven-Membered Rings by Olefin Metathesis" <i>Tetrahedron</i> , 55(27): 8199-8214,				
	1999.					
	*Winssinger, et al., "Epothilones and Sarce	odictyins: From Combinator	rial Libraries to Designed			
	Analogs" Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30,					
	ORGN-289, 2000. *Wittmann, et al., Flavopiridol Down-Regu	ulates Antiapoptotic Proteins	and Sensitizes Human			
	Breast Cancer Cells to Epothilone B-induc	ed Apoptosis, Cancer Resea	rch, 63: 93-99, 2003.			
	*Wolff, A., "Epothilone A Induces Apopto	sis in Neuroblastoma Cells	with Multiple Mechanism			
	of Drug Resistance", Int. J. Oncol., 11(1):	123-126, 1997.	1.4			
1	*Woltering, et al., Development of a Nove	I In Vitro Human Tissue-Bas	sed Angiogenesis Assay to			
- $$	Evaluate the Effect of Antiangiogenic Drug	gs, Annais of Surgery, 231:	790-800, 2003.			

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office			IN RE APPLICATION NO.: 10/726,386		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Danisl	nefsky et al		
		FILING DATE: December 2, 2003	GROUP:		
40	Int. Ed., 30	al., "Total Synthesis of Epothil 6: 166-168, 1997.			
	Suggestive 2518-2521	ra, et al., Synthesis ad Conform Link between the Chemistry a , 2003.	and Biology of Epothilones, A	ngew. Chem. Int. Ed.42:	
	*Zhou, et al., Brominated Derivatives of Noscapine Are Potent Microtubule-Interfering Agents That Perturb Mitosis and Inhibit Cell Proliferation, Molecular Pharmacology, 63: 799-807, 2003.				
	Natural Pr	., "Methodology Based on Chi oducts-Total Synthesis of Epot	thilone A" Eur. J. Org. Chem.,	, 9 : 1701-1714 , 2001.	
	National A	., "Studies Toward the Total Steeting, Boston, August 23-27,	-ORGN-660 No Y	egv	
40	*Zhu, et al C12-C21 I	"Enzymatic Resolution of The Tragment of the Epothilones" 7	hiazole-Containing Vinyl Cart Fetrahedron Lett., 41 (12): 186	3-1866, 2000.	
	*Zhu, et al "Studies Toward the Total Synthesis of Epothilone A" Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-060, 2000.				
V	*Zhu, et al., "Total Synthesis of Epothilone A" Org. Lett., 2(17): 2575-2578, 2000.				
EXAMINER	. <	T. A. 5010) (a DATE CONSI	DERED 8-18-05	

through citation if not in conformance and not considered. Include copy of this form with next communication to

3671140

applicant.

FORM PTO-1400 U.S. Department of Commerce (REV. 8-83) TO TOTAL PARTIES AT THE PROPERTY OF THE PARTIES AT THE PA			ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLIC NO.: 10/726,3	
y Itamanan		STATEMENT	APPLICANT: Danishefsky et al		
NFORMATION DESCRIPTION (Use several sheets if necessary)		FILING DATE:	GROUP	:	
(05055		,,	DECEMBER 2, 2003		
TIS PATENT	DOCUMENTS				
Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Initials	0.5.1 atom 110.	· .pp			
YD	5,021,430	Ksander, et al.	June 4, 1991	514	332
	5,917,084	Jiang, et al.	June 29, 1999	560	174
_		Schinzer, et al.	October 19, 1999	548	110
	5,969,145		March 28, 2000	548	110
	6,043,372	Schinzer, et al.			
	6,156,905	Schinzer et al.	December 5, 2000	548	204
	6,262,094	Höfle, et al.	July 17, 2001	514	365
	6,284,781	Danishefsky, et al.	September 4, 2001	514	365
	6,288,237	Höfle, et al.	September 11, 2001	548	203
	6,291,684	Borzilleri, et al.	September 18, 2001	548	961
	6,302,838	O'Reilly et al	October 16, 2001	574	365
	6,303,342	Julien	October 16, 2001	435	76
	6,303,767	Betlach	October 16, 2001	536	23.2
	6,320,045	Kim, et al.	November 20, 2001	540_	463
	6,350,878	Altmann, et al.	February 26, 2002	548	110
	6,359,140	Höfle, et al.	March 19, 2002	548	204
	6,365,749	Kim et al.	April 2, 2002	548	204
	6,380,227	Mutz	April 30, 2002	514	365
	6,380,394	Nicolaou	April 20, 2002	548	125
	6,380,395	Vite	April 30, 2002	548	146
	6,383,787	Schupp	May 7, 2002	435	183
	6,384,230	Mulzer	May 7, 2002	548	203
	6,387,927	Altmann	May 14, 2002	514	311
_	6,399,638	Vite	June 4, 2002	514	366
	6,410,301	Julien	June 25, 2002	435	252.3
	6,419,692	Yang et al.	July 16, 2002	623	115
	6,441,186	Nicolaou et al.	August 27, 2002	548	204
	6,457,303	Georg et al.	October 1, 2002	56	465
	6,515,017	Li et al.	February 4, 2003	514	449
	6,518,421	Li et al.	February 11, 2003	540	462
	6,525,197	Furstner et al.	February 25, 2003	544	310
\	6,531,497	Nicolaou et al.	March 11, 2003	514	370

Commerc		Department of nerce	ATTY. DOCKET: 2003080-0143	IN RE APPLIC	ATION
		and Trademark Office	(SK-744-CON9)	NO.: 10/726,386	
INFORMATI	ON DISCLOSURE	STATEMENT	APPLICANT: Danishefsky et al		
(Use se	(Use several sheets if necessary)		FILING DATE:	GROUP:	· · · · · · · · · · · · · · · · · · ·
			DECEMBER 2, 2003		
40	6,537,988	Lee	March 25, 2003	514.	221
	6,538,038	Pero et al.	March 25, 2003	514	731
	6,544,544	Hunter et al.	April 8, 2003	424	424
	6,576,651	Bandyopadhyay et al.	June 10, 2003	514	365
	6,593,115	Vite et al.	July 15, 2003	435	134
	6,596,875	White et al.	July 22, 2003	548	204
	6,603,015	Georg et al.	August 5, 2003	548	203
	6,603,023	Danishefsky et al.	August 5, 2003	549	346
	6,605,599	Vite et al.	August 12, 2003	514	63
	6,605,726	Mulzer et al.	August 12, 2003	548	202
	6,610,736	Klar et al.	August 26, 2003	514	450
	6,613,912	Hoefle et al. Hoefle et al.	September 2, 2003 September 23, 2003	548 548	204
	6,624,310				
	6,625,666	O'Reilly et al.	October 21, 2003	710	5
	6,686,380	Lee	February 3, 2004	514	365
	6,689,802	DiMarco et al.	February 10, 2004	514	365
	6,719,540	Regueiro-Ren et al.	April 13, 2004	417	365
	6,723,854	Danishefsky et al.	April 20, 2004	548	203
	6,727,276	Lee	April 27, 2004	514	540
	6,730,699	Li et al.	May 4, 2004	514	449
	6,730,803	Iwasaki et al.	May 4, 2004	558	442
	6,780,620	Li et al.	August 24, 2004	435	117
	6,800,653	Regueiro-Ren et al.	October 5, 2004	514	365
u.s. patent	APPLICATIONS			-	
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit
V. 0	2001/0031880	Borzilleri et al.	October 18, 2001		
	2001/0034452	Hoefle et al.	April 16, 2001		
	2001/0051356	Khosla	December 13, 2001		
	2002/0002162	Lee	January 3, 2002		

FORM PTO-1 (REV. 8-83)	Comm	Department of nerce and Trademark Office	ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.:
(REV. 0-05)			10/726,386	
	ON DISCLOSURE		APPLICANT: Danishefs	
(Use se	veral sheets if necesso	ary)	FILING DATE: DECEMBER 2, 2003	GROUP:
70	2002/0004229	Santi et al.	January 10, 2002	
	2002/0010328	Reeves et al.	January 24, 2002	
	2002/0028839	O'Reilly et al.	March 7, 2002	
	2002/0042109	Vite et al.	April 11, 2002	
	2002/0045220	Khosla et al.	April 18, 2002	
	2002/0045609	Ashley et al.	April 18, 2002	
	2002/0052028	Santi et al.	May 2, 2002	
	2002/0058286	Danishefsky et al.	May 16, 2002	
	2002/0058817	Danishefsky et al.	May 16, 2002	
	2002/0062030	White et al.	May 23, 2002	·
	2002/0065295	Chu et al.	May 30, 2002	
	2002/0143026	Lombardo et al.	October 3, 2002	
	2002/0143038	Bandyopadhyay et al.	October 3, 2002	
	2003/0203938	Nicolaou et al.	October 30, 2003	
	2003/0203929	Ghosh	October 30, 2003	
•	2003/0203876	Hoogevest	October 30, 2003	·
	2003/0194787	Hofmann et al	October 16, 2003	
	2003/0191089	Regueiro-Ren et al.	October 9, 2003	
	2003/0187273	White et al.	October 2, 2003	
	2003/0187039	Favreau et al.	October 2, 2003	
	2003/0186983	Mastalerz et al.	October 2, 2003	
	2003/0186965	Vite et al.	October 2, 2003	
	2003/0180760	Basch et al.	September 25, 2003	
	2003/0176710	Klar et al.	September 18, 2003	
	2003/0176473	Taylor et al.	September 18, 2003	
	2003/0176368	Danishefsky et al.	September 18, 2003	
	2003/0176320	Li et al.	September 18, 2003	
	2003/0171596	Danishefsky et al.	September 11, 2003	
	2004/0023345	Vite et al.	February 5, 2004	
	2004/0024032	Voi et al.	February 5, 2004	

FORM PTO-14 (REV. 8-83)	Comn	Department of nerce and Trademark Office	ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.:
(1207, 5-05)		(512 / 17 0017)	10/726,386	
INFORMATIO	N DISCLOSURE	STATEMENT	APPLICANT: Danishefs	ky et al
(Use sev	eral sheets if necessi	ary)	FILING DATE: DECEMBER 2, 2003	GROUP:
Yo	2004/0024033	O'Reilly et al.	February 5, 2004	
	2004/0030147	White et al.	February 12, 2004	
	2004/0038324	Atadja et al.	February 26, 2004	
	2004/0039026	Nicolaou et al.	February 26, 2004	
	2004/0044203	Wittman et al.	March 4, 2004	
	2004/0044221	Danishefsky et al.	March 4, 2004	
	2004/0049051	Hoefle et al.	March 11, 2004	·
	2004/0053910	Danishefsky et al.	March 18, 2004	
	2004/0053978	Lee et al.	March 18, 2004	
	2004/0053995	Danishefsky et al.	March 18, 2004	
	2004/0054186	Das et al.	March 18, 2004	
	2004/0054188	Kusters et al.	March 18, 2004	
	2004/0058899	Klimko	March 25, 2004	
	2004/0058969	Buchmann et al.	March 25, 2004	
	2004/0062810	Hunter et al.	April 1, 2004	
	2004/0063707	Bhide et al.	April 1, 2004	
	2004/0063708	Bhide et al.	April 1, 2004	
	2004/0063712	Salvati et al	April 1, 2004	
	2004/0063715	Paruch et al.	April 1, 2004	
	2004/0072760	Carboni et al.	April 15, 2004	
	2004/0072832	Bhide et al.	April 15, 2004	
	2004/0072835	Paruch et al.	April 15, 2004	
	2004/0072870	Nicolaou et al.	April 15, 2004	
	2004/0072882	Johnson et al.	April 15, 2004	
	2004/0076672	Hunter et al.	April 22, 2004	
	2004/0077696	Borzilleri et al.	April 22, 2004	
	2004/0082651	Wessjohann et al.	April 29, 2004	
	2004/0087610	Pardee et al.	May 6, 2004	
	2004/0087634	Hoefle et al.	May 6, 2004	
	2004/0092478	Rothermel et al.	May 13, 2004	

FORM PTO-1 (REV. 8-83)	Comm	epartment of erce and Trademark Office	ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLIC NO.:	
		10/726		,386	
	ON DISCLOSURE S		APPLICANT: Danishefs		
(Use se	veral sheets if necessa	(vr) 	FILING DATE: DECEMBER 2, 2003	GROUP	:
40	2004/0092514	Velaparthi et al.	May 13, 2004		
	2004/0092560	Hoefle et al.	May 13, 2004		
	2004/0097516	Dwyer et al.	May 20, 2004		
	2004/0102451	Guzi et al.	May 27, 2004		
	2004/0102452	Guzi et al.	May 27, 2004		
	2004/0102495	Danishefsky et al.	May 27, 2004		
	2004/0106624	Guzi et al.	June 3, 2004		
	2004/0106985	Jang	June 3, 2004		
	2004/0116442	Guzi et al.	June 17, 2004		
	2004/0126379	Adolf et al.	July 1, 2004		
	2004/0127432	Nicolaou et al.	July 1, 2004		
	2004/0132146	Benigni et al.	July 8, 2004		
	2004/0133271	Jang	July 8, 2004		
	2004/0132692	Sherrill et al.	July 8, 2004		
	2004/0132736	Guzi et al.	July 8, 2004		
	2004/0132754	Brandt et al.	July 8, 2004		
	2004/0142931	Vite et al.	July 22, 2004		
	2004/0142990	Hofmann et al.	July 22, 2004		
	2004/0152708	Li et al.	August 5, 2004		
	2004/0157897	DiMarco et al.	August 12, 2004		
	2004/0167083	Bosslet et al.	August 26, 2004		
	2004/0167097	Zhou et al.	August 26, 2004		
	2004/0176429	Li et al.	September 9, 2004		
V	2004/0192621	Nihei et al.	September 30, 2004		
FOREIGN PA	TENT DOCUMENT	S			
Examiner's	Document No.	Country	Date Train	Translat	tion
Initials				Yes	No
Yo	DE 195 42 986.9	Germany	17 November 1995		
	DE 196 39 456.2	Germany	25 September 1996		

FORM PTO-14	Comm		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION
(REV. 8-83)	Patent	and Trademark Office	(SK-744-CON9)	NO.: 10/726,386
INFORMATIO	ON DISCLOSURE S	STATEMENT	APPLICANT: Danishefs	ky et al
(Use sev	eral sheets if necessa	(עיזו)	FILING DATE:	GROUP:
		,	DECEMBER 2, 2003	<u> </u>
70	DE 196 45 361	Germany	30 April 1998	
	DE 196 45 362	Germany	30 April 1998	
	EP 1 440 973	Europe	July 28, 2004	
	EP 1 428 826	Europe	June 16, 2004	
	EP 1 407 784	Europe	April 14, 2004	
	EP 1 386 922	Europe	February 4, 2004	
	EP 1 080 082	Europe	October 6, 2004	
	WO 04/087045	International	October 14, 2004	
	WO 04/085421	International	October 7, 2004	
	WO 04/080458	International	September 23, 2004	
	WO 04/063151	International	July 29, 2004	
	WO 04/061116	International	July 22, 2004	
	WO 04/056832	International	July 8, 2004	
	WO 04/054624	International	July 1, 2004	
	WO 04/054622	International	July 1, 2004	
	WO 04/054514	International	July 1, 2004	
	WO 04/052401	International	June 24, 2004	
	WO 04/052361	International	June 24, 2004	
	WO 04/052237	International	June 24, 2004	
	WO 04/050089	International	June 17, 2004	
	WO 04/050057	International	June 17, 2004	
	WO 04/048372	International	June 10, 2004	
	WO 04/043954	International	May 27, 2004	
	WO 04/043454	International	May 27, 2004	
	WO 04/043400	International	May 27, 2004	·
	WO 04/043363	International	May 27, 2004	
	WO 04/035050	International	April 29, 2004	
	WO 04/032923	International	April 22, 2004	
	WO 04/032872	International	April 22, 2004	
	WO 04/032866	International	April 22, 2004	

ORM PTO-14	Comm		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION
EV. 8-83)	Patent	and Trademark Office	(SK-744-CON9)	NO.: 10/726,386
FORMATIO	N DISCLOSURE S	STATEMENT	APPLICANT: Danishefs	
(Use seve	ral sheets if necessa	ry)	FILING DATE: DECEMBER 2, 2003	GROUP:
70	WO 04/030627	International	April 15, 2004	
	WO 04/030620	International	April 15, 2004	
	WO 04/028610	International	April 8, 2004	
	WO 04/028582	International	April 8, 2004	
	WO 04/026877	International	April 1, 2004	
	WO 04/026872	International	April 1, 2004	
	WO 04/026867	International	April 1, 2004	
	WO 04/026310	International	April 1, 2004	
	WO 04/026229	International	April 1, 2004	·
	WO 04/024735	International	March 25, 2004	
	WO 04/022560	International	March 18, 2004	
	WO 04/022080	International	March 18, 2004	
	WO 04/022062	International	March 18, 2004	
·	WO 04/018635	International	March 4, 2004	
	WO 04/016269	International .	February 26, 2004	<u>.</u>
	WO 04/012735	International	February 12, 2004	
	WO 04/007476	International	January 22, 2004	
	WO 03/096975	International	November 27, 2003	
	WO 03/057830	International	17 July 2003	
	WO 02/096281	International	December 5, 2004	
	WO 02/046196	International	13 June 2002	·
	WO 02/042432	International	30 May 2002	
	WO 02/032844	International	16 October 2001	
	WO 99/028324	International	10 June 1999	
	WO 99/003848	International puly	28 January 1999	
	WO 95/003035	International 4	2 February 1995	
	WO 93/010121	International	27 May 1993	

FORM PTO-144	10 IIC Department of	ATTY. DOCKET:	IN RE		
FURM P10-144	U.S. Department of Commerce	2003080-0143	APPLICATION		
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON9)	NO.:		
(REV. 0-03)	Tatent and Trademark Office	(SK-744-CON9)	10/726,386		
INFORMATIO	N DISCLOSURE STATEMENT	APPLICANT: Danishefsky	y et al		
(Use seve	ral sheets if necessary)	FILING DATE:	GROUP:		
		DECEMBER 2, 2003			
4,0	Altmann et al., "Epothilone B and Its Anal- Rev. Med. Chem. 3:149, 2003.	ogs -A New Family of Antic	ancer Agents" Mini-		
	Baggiolini et al., "Stereocontrolled Total S	-	ycholecalciferol and		
	1α, 25-Dihydroxyergocalciferol" J. Org. C	hem. 5 1:3098-3108, 1986.			
	Balog et al., "Stereoselective Syntheses and Desmethylepothilone A Series: Some Surp (1997).	d Evaluation of Compounds rising Observations" Tet. Lett	in the 8- 2. 38: (26): 4529-4532		
	Bijoy et al., "Synthetic Studies Directed To	owards Epothilone A" Tet. L	ett. 39:209-212, 1998.		
	Bollag et al., "Epothilones, a New Class of 55:2325-2333, 1995.	MT-stabilizing Agents " Ca	ncer Research		
	Bollag et al., "Epothilones: Novel Microtul 6(7):867-873, 1997.				
	Chakraborty et al., "Radical-induced Opening of Trisubstituted Epothilones" Tet. Lett. 3 104, 1998.				
	Chakravarty et al., "Taxoid and Non-Taxoi	d Inhibitors of Microtubule	Disassembly:		
	Molecular Modeling Approach to Eludication of a Common Pharmacophore" Book of				
	Abstracts, 214th ACS National Meeting, Las Vegas, NV, September 7-11, MEDI-075.				
	American Chemical Society. Chou et al., "Quantitative Analysis of Dose	Effect Deletionshine The C	ombined Effects of		
	Multiple Drugs or Enzyme Inhibitors" Adv				
	Chou et al., "Design and Total Synthesis of				
·	which Eliminate Xenograft Tumors to a Nonrelapsable State" Angew. Chem. Int. Ed. Engl. 42:4762-4767, 2003.				
	Ermolenko et al., "Synthesis of Epothilone 2898, 2002.	s B and D from D-Glucose"	Tet. Lett. 43:2895-		
	Fletcher et al., "Structure of the Mitogen-In	nducible TIS10 Gene and De	monstration That the		
	TIS10-Encoded Protein Is a Functional Pro 4344, 1992.				
	Giannakakou et al., "Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins" J. Biol. Chem. 272(27):17118-17125, 1997.				
	Haar, et al., "Discodermolide, A Cytotoxic Potently Than Taxol", Biochemistry, 35: 24	43-250, 1996.			
	Harris, et al., "Chemical Synthesis and Bio Stabilizing Agents with Enhanced Activity Tumors", Chemistry for the 21st Century, 8	Against Multidrug-Resistan	lones – Microtubule t Cell Lines and		
	Hofle et al., "Epothilone A and B – Novel Isolation, Crystal Structure, and Conforma 35:1567-1569, 1996.	16-Membered Macrolides w	ith Cytotoxic Activity: em. Int. Ed. Engl.		

FORM PTO-144	-	ATTY. DOCKET:	IN RE	
	Commerce	2003080-0143	APPLICATION	
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON9)	NO.:	
			10/726,386	
INFORMATIO	N DISCLOSURE STATEMENT	APPLICANT: Danishefsky	et al	
(Use seve	ral sheets if necessary)	FILING DATE:	GROUP:	
		DECEMBER 2, 2003		
70	Hofle, et al., "N-Oxidation of Epothilone A			
	Substituted Epothilones" Angew. Chem. In	t. Ed., 38(13/14):19/1-19/4,	1999.	
	Kowalski et al., "Activities of the Microtub Biol. Chem. 272:4 2534-2541 (1997).	oule-stabilizing Agents Epoth	niones A and B, J.	
	Levin, et al., "An Alternative Procedure for	the Aluminum-Mediated Co	nversion of Esters to	
	Amides", Synth. Commun. 12: 989, 1982. Lindel, et al., "Eleutherobin, A New Cytoto	win that Mimica Daalitaval ("	Caval) by Stabilizing	
	Microtubules", J. Am. Chem. Soc. 119: 874		Taxon) by Stabilizing	
	Liu et al., "Chiral Synthesis of the C ₃₋₁₃ Se (1997)		ett Letters 1383-84	
	Lythgoe, et al., "Allylic Phosphine Oxides	as Precursors of Dienes of Do	efined Geometry:	
	Synthesis of 3-Deoxyvitamin D ₂ ", Tetrahe	dron Lett. 40:3863-3866, 197	5.	
	Lythgoe, et al., "Synthetic Approaches to Vitamin D and its Relatives", Chem. Soc. Rev. 449-475, 1981.			
	March, Advanced Organic Chemistry, 2nd	Ed., McGraw-Hill (1977), pa	ge 940, section 7-21	
	Meng et al. "Total Synthesis of Epothilones A and B" J. Am. Chem. Soc. 119:42 10073-10092 (1997).			
	Meng et al. "Studies toward a Synthesis of the Management of Acyclic Stereochemica (1996).	Epothilone A: Use of Hydrop l Relationships" J. Org. Chem.	byran Templates for n. 61:23 7998-8001	
	Moasser et al., "Farnesyl transferase inhibi Proc. Natl. Acad. Sci. USA, 95:1369-1374		ensitivity to taxol"	
	Mooberry, et al., "Laulimalide and Isolauli Stabilizing Agents", Cancer Res. 59: 653-6	malide, New Paclitaxel-Like	Microtubule-	
	Muhlradt et al., "Epothilone B Stabilizes M. Res. 57, 3344-46 (1997).		ike Taxol", Cancer	
	Mulzer, J. et al., "Synthesis of the C(1)-C(9) A and B", Tetrahedron Letters 37:51, 9179		Macrolides Epothilon	
	Nagaoka, et al., "Further Synthetic Studies 1981.	on Rifamycin S", Tetrahedro	on, 37 : 3873-3888,	
	Nahm, et al., "N-Methoxy-N-Methylamide 22: 3815-3818, 1981.	s as Effective Acylating Age	nts", Tetrahedron Lett.	
	Nicolaou, et al., "Chemistry and Biology o 1994.	f Taxol", Angew. Chem. Int.	Ed. Engl. 33: 15-44,	
	Nicolaou, et al., "Total Synthesis of Epothi through the Stille Coupling Reaction" Ange			
	Nicolaou, K.C. et al. "Total Synthesis of E Chains through the Stille Coupling Reaction	pothilone E and Analogues w	rith Modified Side	
	Nicolaou, K.C. et al., "Total Synthesis of E	Inothilone A. The Macrolacto	nization Approach"	
V	inicoladu, K.C. et al., I diai Syllinesis di E	Poumone A. The Macrolacte	incurrent reproduit,	

	10 110 5	ATTIL DOCKET.	DIDE	
FORM PTO-144	U.S. Department of Commerce	ATTY. DOCKET:	IN RE APPLICATION	
(DETT. 0.04)	-	2003080-0143	NO.:	
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON9)	10/726,386	
INFORMATIO	N DISCLOSURE STATEMENT	APPLICANT: Danishefsky	y et al	
(Use seve	ral sheets if necessary)	FILING DATE:	GROUP:	
		DECEMBER 2, 2003	•	
70	Angew Chem. Int. Ed. Engl., 36:525-527 (1	997).		
	Nicolaou, K.C. et al., "Total Synthesis of C	xazole-and Cyclopropane-C	ontaining Epothilone A	
	Analogues", Chem. Eur. J. 3:12 1957-197	70 (1997).	4 ' ' D 4 ' D	
	Nicolaou, K.C. et al., "Total Synthesis of C	exazole-and Cyclopropane-Co	ontaining Epothilone B	
	Analogues", Chem. Eur. J. 3:12 1971-198 Nicolaou, K.C. et al., "Designed Epothilone	30 (1997).	Tubulin Assembly "	
	Agnew Chem. Int. Ed. Engl. 36:19 2097-21		Tuounn 7135cmory	
	Nicolaou, K.C. et al., "Total Synthesis of 2	6-Hydroxy-Epothilone B and	l Related Analogs via a	
	Macrolactonization Based Strategy" Tetrah	nedron 54 : 7127-7166 (1998)		
	Nicolaou, K.C. et al. "Total Synthesis of Ep	oothilone A and B via a Mac	rolactonization-Based	
	Strategy", J. Am. Chem. Soc. 119:7974-799	1 (1997).		
	Nicolaou, K.C. et al., "Synthesis of Epothil	ones A and B in solid and so	lution phase", Nature	
	387 :15 268-272, 238-239 (1997).	4.11 - D 1 Olofin M.	-tathanial America	
	Nicolaou, K.C. et al., "An Approach to Epo	othilones Based on Olelin Me	etatnesis" Angew.	
	Chem. Int. Ed. 35:20 2399-2401 (1996).	Il Migration Inhibitors Throu	igh Total Synthesis:	
	Njardarson, et al., "Discovery of Potent Cell Migration Inhibitors Through Total Synthesis: Lessons from Structure – Activity Studies of (+)- Migrastatin", J. Am. Chem. Soc. 126:1038-			
	1040, 2004.			
	Noyori, et al., "Asymmetric Hydrogenation	of β-Keto Carboxylic Esters	s. A Practical, Purely	
	Chemical Access to β-Hydroxy Esters in H	ligh Enantiomeric Purity" J.	Am. Chem. Soc. 109:	
	5856-5859, 1987.			
	Ojima, et al., "Enantiopure Fluorine-Conta	ining Taxoids: Potent Antica	ncer Agents and	
	Versatile Probes for Biomedical Problems' Paterson et al., "Stereocontrolled Aldol Ad			
	Application to the Synthesis of a C ₁₃ -C ₂₅ S	egment of Bafilomycin A ₁ "	Tetrahedron Lett.	
	36:175-178, 1995.	G ,		
	Pettet et al., "Isolation and Structure of the	Cancer Cell Growth Inhibito	or Dictyostatin 1", J.	
	Chem. Soc. Chem. Commun. 1111-1112, 19	994.		
	Roush et al., "Acyclic Diastereoslective Sy	nthesis Using Tartrate Ester	Modified	
	Crotylboronates. Double Asymmetric Rea	ctions with α -Methyl Chiral	Aldehydes and	
	Synthesis of the C(19)-C(29) Segment of F	Kitamycin S. J. Am. Chem. S	oc. 112.0348-0339,	
	1990. Sawada et al., "Enantioselective Total Syn	thesis of Epothilones A and I	B Using	
	Multifunctional Asymmetric Catalysis" J.	Am. Chem. Soc. 122(43):105	21-10532, 2000.	
	Schiff et al., "Promotion of Microtubule A	ssembly in vitro by Taxol" A	lature, 277:665-667,	
	1979.			
	Scholl et al., "Increased Ring Closing Met	athesis Activity of Rutheniur	n-Based Olefin	
1),	Metathesis Catalysts Coordinated with Imi	dazolin-2-Ylidene Ligands",	Tetrahedron Lett.	
H \\/	40:2247-2250, 1999			

FORM PTO-1	U.S. Department of	ATTY. DOCKET:	IN RE		
	Commerce	2003080-0143	APPLICATION		
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON9)	NO.:		
			10/726,386		
INFORMATIO	ON DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al			
(Use sev	veral sheets if necessary)	FILING DATE:	GROUP:		
		DECEMBER 2, 2003	0.0		
40	Scudiero et al., "Evaluation of a Soluble To Drug Sensitivity in Culture Using Human a				
	4833, 1988. Schinzer et al., "Studies Toward the Total	Synthesis of Epothilones"	Chem. Eur. J.		
	2(11):1477-1488, 1996.		T . E ! 26 5 502 504		
	Schinzer et al., "Total Synthesis of ()-Epot 1997.				
	Sefkow et al., "Substitution at the Thiazole 1998.				
	Sinha et al., "Regioselective Synthesis of F Syntheses via Antibody Catalysis" Tetrahe	luoro Aldols. Studies Towdron Letters, 41(43):8243	vard Fluro Epothilones -8246, 2000.		
	Stachel et al., "On the Interactivity of Complex Synthesis and Tumor Pharmacology in the				
	Drug Discovery Process: Total Synthesis a Epothilones" J. Org. Chem. 66:4369-4378,	and Comparative in Vivo I	Evaluations of the 15-Aza		
	Su et al., "Total Synthesis of (-) Epothilone	B: An Extension of the S	uzuki Coupling Method		
	and Insights into Structure-Activity Relation Engl. 36:757-759, 1997.	nships of the Epothilones'	', Angew. Chem. Int. Ed.		
	Sun et al. "Stereoselective Total Synthesis	Sun et al. "Stereoselective Total Synthesis of Epthilones by the Metathesis Approach involving C9-C10 Bond Formation" Angew. Chem. Int. Ed. 8:1381-1383, 2002.			
	Toh et al., "Studies on a Convergent Route to Side-Chain Analogues of Vitamin D: 25- Hydroxy-23-Oxavitamin D ₃ " J. Org. Chem. 48:1414-1417, 1983.				
	Tsuji et al., "Alterations in Cellular Adhesi	on and Apoptosis in Epith			
	Overexpressing Prostaglandin Endoperoxic Victory et al., "Relative Stereochemistry at Like Antimitotic Agent Epothilone A" Bio 898, 1996.	nd Solution Conformation	of the Novel Paclitaxel-		
	Wessjohann, "Epothilones: Promising Nati Chem. Int. Ed. Engl. 36(7):715-718, 1997.	ural products with Taxol-L	ike Activity" Angew.		
	White et al. "Synthesis, Conformational A.D" Organic Letters 4:995-997, 2002.				
V	Wu et al. "Subtle Variations in the Long-Range Transmission of Stereochemical Information: Matched and Mismatched Aldol Reactions" Angew. Chem. Int. Ed. 39(24):4505-4508 (2000).				
EXAMINER	T. A. Solola	DATE CONSID	0 10 11		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.